Loading...

OMER OMEROS CORP US FDA Inspections 8-K Filing

MRS

MR

OMEROS CORP

(OMER)

2025 8-K

Summary

Summary

Asset Agreement

Financial Results Announced

Equity Offerings

Correction of Exhibit

Debt Restructuring

Clinical Trials

Financial Results

Statistical Analysis

Statistical Analysis

Statistical Analysis

Financial Results

Earnings Reports

Management Changes

Entry into a Definitive Mat...

Financial Results Announcement

Earnings Reports

Entry into a Definitive Mat...

Earnings Reports

Phase 3 Trial Results

Earnings Reports

Amendment of 2017 Omnibus I...

Appointment of Director

Earnings Reports

Financial Results Announcement

Results of Operations and F...

External Links:

On May 6, 2025, Omeros Corporation announced that the FDA accepted its application for review of narsoplimab, intended for treating a serious blood-related condition after stem cell transplants.

AI Assistant

OMEROS CORP

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.